Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model

Human Gene Therapy

Volumn 8, Issue 9, 1997, Pages 1073-1085

  Parney, Ian F ^a   Petruk, Kenneth C ^a   Zhang, Chengsheng ^a   Farr Jones, Maxine ^a   Sykes, David B ^a   Chang, Lung Ji ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; RETROVIRUS; SCID MOUSE;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0030743966     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.9-1073     Document Type: Article

References (88)

1. AGLIETTA, M., PIACIBELLO, W., PASQUINO, P., SANAVIO, F., STACHINI, A., VOLTA, C., MONTEVERDE, A., FABINI, L., MORELLI, S., and SEVERINO, A. (1994). Rationale for the use of granulocyte-macrophage colony-stimulating factor. Semin. Oncol. 21, 5-9.
2. ALEGRE, M.L., PETERSON, L.J., JEYARAJAH, D.R., WEISER, M., BLUESTONE, J.A., and THISTLETHWAITE, J.R. (1994). Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J. Immunol. 153, 2738-2749.
3. BARBA, D., HARDIN, J., RAY, J., and GAGE, F. (1993). Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729-735.
4. BARKER, M., HOSHINO, T., GURCAY, O., WILSON, C.B., NIELSON, S.L., DOWNIE, R., and ELIASON, J. (1973). Development of a brain tumor animal model and its response to 1,2 bis-(2-chlorethyl)1-nitrosurea. Cancer Res. 33, 976-981.
5. BASKAR, S., OSTRAND-ROSENBERG, S., NABAVI, N., NADLER, L., FREEMAN, G., and GLIMCHER, L. (1993). Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90, 5687-5690.
6. BASKAR, S., GLIMCHER, L., NABAVI, N., JONES, R., and OSTRAND-ROSENBERG, S. (1995). Major histocompatibility complex class II + B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629.
7. BENDA, P., LIGHBODY, J., SATO, G., LEVINE, L., and SWEET, W. (1968). Differentiated rat glial cell strain in tissue culture. Science 161, 370-372.
8. BERNS, A., CLIFT, S., COHEN, L., DONEHOWER, R., DRANOFF, G., HAUDA, K., JAFFEE, E., LAZENBY, A., LEVITSKY, H., and MARSHALL, F. (1995). Clinical protocol: Phase I study of nonreplicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 6, 347-368.
9. BLACK, K.L., CHEN, K., BECKER, D.P., and MERRILL, J.E. (1992). Inflammatory leukocytes associated with increase immunosuppression by glioblastoma. J. Neurosurg. 77, 120-126.
10. BOSMA, G.C., CUSTER, R.P., and BOSMA, M.J. (1983). A severe combined immunodeficiency mutation in the mouse. Nature 301, 527-530.
11. BOUSSIOTIS, V.A., FREEMAN, G.J., GRIBBEN, J.G., DALEY, J., GRAY, G., and NADLER, L.M. (1993). Activated human B lymphocytes express three CTLA-4 counter receptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90, 11059-11063.
12. CHANDLER, C., and PASSARO, E. (1993). Transplant rejection. Arch. Surg. 128, 279-283.
13. CHANG, C., FURUE, M., and TOMAKI, K. (1995). B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines and is down-regulated by interferon-gamma or by interleukin-10. Eur. J. Immunol. 25, 394-398.
14. CHANG, C., HORTON, J., SCHOENFELD, D., SALAZER, O., PEREZ-TAMAZO, R., KRAMER, S., WEINSTEIN, A., NELSON, J., and TSUKADA, Y. (1983). Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52, 997-1007.
15. CHANG, L.-J., and ZHANG, C. (1995). Infection and replication of Tat-minus human immunodeficiency viruses: genetic analyses of LTR and tat mutants in primary and longterm human lymphoid cells. Virology 211, 157-169.
16. CHANG, L.-J., ZHANG, C., ROBINSON, D., and DICKIE, P. (1996). Murine models for the evaluation of anti-HIV strategies. Transf. Sci. 17, 89-98.
17. CHEN, L., ASHE, S., BRADY, W., HELLSTROM, I., HELLSTROM, K., LEDBETTER, J., MCGOWAN, P., and LINSLEY, P. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
18. CHEN, L., MCGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTROM, I., and HELLSTROM, K. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J. Exp. Med. 179, 523-530.
19. CHONG, H., HUTCHINSON, G., HART, J.R., and VILE, R.G. (1996). Expression of co-stimulatory molecules by tumor cells decreased tumorigenicity but may also reduce systemic antitumor immunity. Hum. Gene Ther. 7, 1771-1779.
20. CROY, B.A., and CHAPEAU, C. (1990). Evaluation of the pregnancy immunotropism hypothesis by assessment of the reproductive performance of young adult mice of genotype scid/scid.bg/bg. J. Reprod. Fertil. 88, 231-239.
21. CULVER, K, RAM, Z., and WALLBRIDGE, S. (1992). In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 256, 1550-1552.
22. CULVER, K., VAN GILDER, J., LINK, C., CARLSTROM, T., BUROKER, T., YUH, W., KOCH, K., SCHABOLD, K., DORNBAS, S., and WETZEN, B. (1994). Clinical Protocol: Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 343-379.
23. DAY, E.D., and BIGNER, D.D. (1973). Specificity, cross-reactivity, and affinity of I-labelled antiglioma antibodies for monolayers of cultured glioma cells. Cancer Res. 33, 2362-2368.
24. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAURADA, H., PARDOLL, D., and MULLIGAN, R. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
25. ENGELHARD, M., and BRITTINGER, G. (1994). Clinical relevance of granulocyte-macrophage colony-stimulating factor. Sem. Oncol. 21, 1-4.
26. FAKHRAI, H., DORIGO, O., SHAWLER, D.L., LIN, H., MERCOLA, D., BLACK, K.L., ROYSTON, I., and SOBOL, R.E. (1996). Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. 93, 2909-2914.
27. FONTANA, A., KRISTENSEN, F., DUBS, R., GEMSA, D., and WEBER, E. (1982). Production of prostaglandin E and interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J. Immunol. 129, 2413-2419.
28. FREEMAN, G., GRIBBEN, J., BAUSSIOTIES, V., NG, J., RESTIVO, V., LOMBARD, L., GRAY, G., and NADLER, L. (1993). Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T-cell proliferation. Science 262, 909-911.
29. FREEMAN, S., ABBOUD, C., WHARTENLEY, K., PACKMAN, C., KOEPLIN, D., MOOLTEN, F., and ABRAHMI, G. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
30. FUJII, H., INOBE, M., KIMURA, F., MURATA, J., MURAKAMI, M., ONISHI, Y., AZUMA, I., UEDE, T., and SAIKI, I. (1996). Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int. J. Cancer 66, 219-224.
31. GAJEWSKI, T.F., RENAULD, J.C., VAN PEL, A., and BOON, T. (1995). Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154, 5637-5648.
32. GALEA-LAURI, J., FARZANEH, F., and GAKEN, J. (1996). Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther. 3, 202-213.
33. GALLAGHER, G., REES, R., and REYNOLDS, C., EDS. (1993). Tumor Immunobiology: A Practical Approach. (IRL Press at Oxford University Press, New York).
34. GLAS, R., WALDENSTROM, M., HOGLUND, P., KLEIN, G., KARRE, K., and LJUNGGREN, H.-G. (1995). Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex class I expression on the graft. Cancer Res. 55, 1911-1916.
35. GLICK, R.P., LICHTOR, T., KIM, T.S., ILANGOVAN, S., and COHEN, E.P. (1995). Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36, 548-555.
36. HODGE, J., ABRAMS, S., SCHLOM, J., and KANTOR, J. (1994). Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54, 5552-5555.
37. HUANG, A.Y., GOLUMBECK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
38. HUETTNER, C., PAULUS, W., and ROGGENDORF, W. (1995). Messenger RNA: Expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol. 146, 317-322.
39. JAFFEE, E., DRANOFF, G., COHEN, L., HAUDA, K., CLIFT, S., MARSHALL, F., MULLIGAN, R., and PARDOLL, D. (1993). High efficiency gene transfer into primary human tumor expiants without cell selection. Cancer Res. 53, 2221-2226.
40. KAWAMURA, T., and FURUE, M. (1995). Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: Differential regulation by T helper type 1 and T helper type 2 cytokines. Eur. J. Immunol. 25, 1913-1917.
41. KORNBLITH, P.K., WELCH, W.C., and BRADLEY, M.K. (1993). The future therapy for glioblastoma. Surg. Neurol. 39, 538-543.
42. KUPPNER, M., HAMOU, M., SAWAMURA, Y., BODMER, S., and DE TRIBOLET, N. (1989). Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J. Neurosurg. 71, 211-217.
43. LANIER, L., O'FALLON, S., SOMOZA, C., PHILLIPS, J., LINSLEY, P., OKUMURA, K., ITO, D., and AZUMA, M. (1995). CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154, 97-105.
44. LARSEN, C.P., AUSTYN, J.M., PHIL, D., and MORRIS, P.J. (1990). The role of graft-derived dendritic leukocytes in the rejection of vascularized organ allografts. Ann. Surg. 212, 308-317.
45. LEON, S.P., ZHU, J., and MCL. BLACK, P. (1994). Genetic aberrations in human brain tumors. Neurosurgery 34, 708-722.
46. LIESHCKE, G., and BURGESS, A. (1992). Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part 1). N. Engl. J. Med. 327, 28-35.
47. LINSLEY, P., PEACH, R., GLADSTONE, P., and BAJORATH, J. (1994). Extending the B7 (CD80) gene family. Prot. Sci. 3, 1341-1343.
48. MACDOUGAL, J.R., CROY, C., CHAPEAU, C., and CLARK, D. (1990). Demonstration of a splenic cytotoxic effector cell in mice of genotype scid/scid.bg/bg. Cell. Immunol. 130, 106-117.
49. MALKOVSKA, V., CIGEL, F., and STORER, B.E. (1994). Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumor immunity. Clin. Exp. Immunol. 96, 158-165.
50. MATSUMOTO, T., TANI, E., KABA, K., SHINDO, H., and MIYAGI, K. (1991). Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J. Neurosurg. 74, 460-466.
51. MCCUNE, J.M., NAMIKAWA, R., KANESHIMA, H., SHULTZ, L.D., LIEBERMAN, M., and WEISSMAN, I.L. (1988). The SCID-hu Mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 241, 1632-1639.
52. MCDONALD, J., and ROSENBLUM, M. (1994). Gliomas. In Principles of Neurosurgery. S. Regachary and R. Wilkins, eds. (Wolfe Publishing, Toronto) pp. 26.21-26.32.
53. MOLLER, E. (1995). Cell interactions and cytokines in transplantation immunity. Transpl. Proc. 27, 24-27.
54. MONDINO, A., and JENKINS, M.K. (1994). Surface proteins involved in T cell costimulation. J. Leuk. Biol. 55, 805-815.
55. MOSIER, D.E., STELL, K.L., GULIZIA, R.J., TORBETT, B.E., and GILMORE, G.L. (1993). Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J. Exp. Med. 177, 191-194.
56. MUELLER, B.M., ROMERDAHL, C.A., TRENT, J.M., and REISFELD, R. (1991). Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res. 51, 2193-2198.
57. NITTA, T., HISHII, M., SATO, K., and OKAMURA, K. (1994). Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res. 649, 122-128.
58. OLDFIELD, E.H., RAM, Z., CHIANG, Y., and BLAESE, R. (1995). Clinical protocol: intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. Hum. Gene Ther. 6, 55-85.
59. PLUMAS, J., CHAPEROT, L., JACOB, M.-C., MOLENS, J.-P., GIROUX, C., SOTTO, J.-J., and BENSA, J.-C. (1995). Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of costimulatory molecule CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur. J. Immunol. 25, 3332-3341.
60. PROCHAZKA, M., GASKINS, H.R., SHULTZ, L.D., and LEITER, E.H. (1992). The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc. Natl. Acad. Sci. USA 89, 3290-3294.
61. RAFFEL, C., CULVER, K., KOHN, D., NELSON, M., SIEGAL, S., GILLIS, F., LINK, C., VILLABLANCA, J., and ANDERSON, W. (1994). Clinical protocol: gene therapy for the treatment of recurrent pediatric malignant astrocytomas with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 863-890.
62. RAM, Z., CULVER, K., WALLBRIDGE, S., BLAESE, R., and OLDFIELD, E. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
63. REDDY, S., PICCIONE, D., TAKITA, H., and BANKERT, R. (1987). Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res. 47, 2456-2460.
64. ROBEY, E., and ALLISON, J.P. (1995). T-cell activation: Integration of signals of cytokine gene-modified tumor cells. Immunol. Today 16, 306-310.
65. ROBINSON, D., ELLIOTT, J.F., and CHANG, L.J. (1995). Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is upregulated by HIV-1. Tat. Gene Ther. 2, 269-278.
66. SALVADORI, S., GANSBACHER, B., WERNICK, I., TIRELLI, S., and ZIER, K. (1995). B7-1 amplifies the response to interleukin-2 secreting tumor vaccines in vivo, but fails to induce a response to naive cells in vitro. Hum. Gene Ther. 6, 1299-1306.
67. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA 93, 10399-10404.
68. SANDA, M., AYYAGARI, S., JAFFEE, E., EPSTEIN, J., CLIFT, S., COHEN, L., DRANOFF, G., PARDOLL, D., MULLIGAN, R., and SIMONS, J. (1994). Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151, 622-628.
69. SAWAMURA, Y., DISERENS, A.-C., and DE TRIBOLET, N. (1990). In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J. Neuro-Oncol. 9, 125-130.
70. SIEPL, C., BODMER, S., FREI, K., MACDONALD, H., DEMARTIN, R., HOFER, E., and FONTANA, A. (1988). The glioblastoma derived T-cell suppressor factor/transforming growth factor beta 2 inhibits T-cell growth without affecting the interaction of interleukin-2 with its receptor. Eur. J. Immunol. 18, 593-600.
71. SIMPSON, E., FARRANT, J., and CHANDLER, P. (1991). Phenotypic and functional studies of human peripheral blood lymphocyes engrafted in SCID mice. Immunol. Rev. 124, 97-111.
72. SOBOL, R.E., FAKHRAI, H., SHAWLER, D., GJERSET, R., DORIGO, O., CARSON, C., KHALEGHI, T., KOZIOL, J., SHIFTAN, T.A., and ROYSTON, I. (1995). Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2, 164-167.
73. TAKAMIYA, T., SHORT, M., MOOLTEN, F., FLEET, C., MINETS, T., BREAKEFIELD, X., and MARTUZA, R. (1993). An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg. 79, 104-110.
74. TAKAMIYA, Y., SHORT, M.P., EZZEDINE, Z., MOOLTEN, F., BREAKEFIELD, X., and MARTUZA, R. (1992). Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33, 493-503.
75. TAMIYA, T., WEI, M., CHASE, M., ONO, Y., LEE, F., BREAKEFIELD, X., and CHIOCCA, E. (1995). Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther. 2, 531-538.
76. TARY-LEHMANN, M., SAXON, A., and LEHMANN, P.V. (1995). The human immune system in hu-PBL-SCID mice. Immunol. Today 16, 529-533.
77. THOMPSON, C. (1995). Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 71, 979-982.
78. TORBETT, B.E., PICCHIO, G., and MOSIER, D.E. (1991). hu-PBL-SCID mice: A model for human immune function, AIDS, and lymphomagenesis. Immunol. Rev. 124, 139-164.
79. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
80. VAN MEIR, E., POLVERINI, P., CHAZIN, V., SU HUANG, H., DE TRIBOLET, N., and CAVANEE, W. (1994). Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet. 8, 171-176.
81. VILE, R., NELSON, J., CASTLEDEN, S., CHONG, H., and HART, I. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.
82. WU, J., CANO, W., MEYLAERTS, S., QI, P., VRIONIS, F., and CHERINGTON, V. (1994). Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35, 1094-1103.
83. WU, T.-C., HUANG, A., JAFFEE, E., LEVITSKY, H., and PARDOLL, D. (1995). A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182, 1415-1421.
84. YANG, G., HELLSTROM, K.E., HELLSTROM, I., and CHEN, L. (1995). Antitumor immunity elictied by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
85. YU, J., WEI, M., CHIOCCA, A., MARTUZA, R., and TEPPER, R. (1993). Treatment of glioma by engineered interleukin-4 secreting cells. Cancer Res. 53, 3125-3128.
86. YUNG, W.K.A (1994). New approaches to molecular therapy of brain tumors. Curr. Opin. Neurol. 7, 501-505.
87. ZHAI, Y., ESSELMAN, W.J., OAKLEY, C.S., CHANG, C., and WELSCH, C. (1992). Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. Cancer Immunol. Immunother. 35, 237-245
88. ZHANG, C., CUI, Y., HOUSTON, S., and CHANG, L.-J. (1996). Protective immunity to human immunodeficiency virus type 1 in SCID/beige mice reconstituted with peripheral blood lymphocytes of exposed but uninfected individuals. Proc. Natl. Acad. Sci. USA 93, 14720-14725.